Chase Investment Counsel Corp Decreases Stock Holdings in Novo Nordisk A/S (NYSE:NVO)

Chase Investment Counsel Corp lessened its stake in Novo Nordisk A/S (NYSE:NVO) by 86.5% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 6,337 shares of the company’s stock after selling 40,605 shares during the quarter. Chase Investment Counsel Corp’s holdings in Novo Nordisk A/S were worth $754,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. GQG Partners LLC raised its position in shares of Novo Nordisk A/S by 654.6% during the 1st quarter. GQG Partners LLC now owns 3,633,064 shares of the company’s stock worth $466,485,000 after purchasing an additional 3,151,584 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Novo Nordisk A/S by 10,608.4% in the third quarter. International Assets Investment Management LLC now owns 1,813,571 shares of the company’s stock valued at $215,942,000 after acquiring an additional 1,796,635 shares in the last quarter. DSM Capital Partners LLC boosted its stake in shares of Novo Nordisk A/S by 257,816.0% in the second quarter. DSM Capital Partners LLC now owns 1,593,921 shares of the company’s stock worth $227,516,000 after acquiring an additional 1,593,303 shares during the last quarter. Acadian Asset Management LLC increased its position in shares of Novo Nordisk A/S by 1,300.8% during the first quarter. Acadian Asset Management LLC now owns 1,244,128 shares of the company’s stock worth $159,703,000 after purchasing an additional 1,155,313 shares in the last quarter. Finally, Mediolanum International Funds Ltd acquired a new position in Novo Nordisk A/S in the 3rd quarter valued at $98,765,000. 11.54% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities research analysts have issued reports on NVO shares. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $160.00 target price on shares of Novo Nordisk A/S in a research note on Wednesday, November 6th. StockNews.com raised Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research note on Friday, November 1st. Finally, BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a research report on Thursday, October 17th. One research analyst has rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $144.50.

Novo Nordisk A/S Trading Down 1.9 %

Shares of NYSE:NVO opened at $107.05 on Wednesday. The company’s 50 day moving average is $120.23 and its two-hundred day moving average is $130.08. The company has a current ratio of 0.94, a quick ratio of 0.75 and a debt-to-equity ratio of 0.43. The company has a market cap of $480.39 billion, a PE ratio of 34.64, a P/E/G ratio of 1.32 and a beta of 0.42. Novo Nordisk A/S has a 52 week low of $94.73 and a 52 week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.